Koyuncu Emre, Budayeva Hanna G, Miteva Yana V, Ricci Dante P, Silhavy Thomas J, Shenk Thomas, Cristea Ileana M
Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA
mBio. 2014 Dec 16;5(6):e02249-14. doi: 10.1128/mBio.02249-14.
The seven human sirtuins are a family of ubiquitously expressed and evolutionarily conserved NAD(+)-dependent deacylases/mono-ADP ribosyltransferases that regulate numerous cellular and organismal functions, including metabolism, cell cycle, and longevity. Here, we report the discovery that all seven sirtuins have broad-range antiviral properties. We demonstrate that small interfering RNA (siRNA)-mediated knockdown of individual sirtuins and drug-mediated inhibition of sirtuin enzymatic activity increase the production of virus progeny in infected human cells. This impact on virus growth is observed for both DNA and RNA viruses. Importantly, sirtuin-activating drugs inhibit the replication of diverse viruses, as we demonstrate for human cytomegalovirus, a slowly replicating DNA virus, and influenza A (H1N1) virus, an RNA virus that multiplies rapidly. Furthermore, sirtuin defense functions are evolutionarily conserved, since CobB, the sirtuin homologue in Escherichia coli, protects against bacteriophages. Altogether, our findings establish sirtuins as broad-spectrum and evolutionarily conserved components of the immune defense system, providing a framework for elucidating a new set of host cell defense mechanisms and developing sirtuin modulators with antiviral activity.
We live in a sea of viruses, some of which are human pathogens. These pathogenic viruses exhibit numerous differences: DNA or RNA genomes, enveloped or naked virions, nuclear or cytoplasmic replication, diverse disease symptoms, etc. Most antiviral drugs target specific viral proteins. Consequently, they often work for only one virus, and their efficacy can be compromised by the rapid evolution of resistant variants. There is a need for the identification of host proteins with broad-spectrum antiviral functions, which provide effective targets for therapeutic treatments that limit the evolution of viral resistance. Here, we report that sirtuins present such an opportunity for the development of broad-spectrum antiviral treatments, since our findings highlight these enzymes as ancient defense factors that protect against a variety of viral pathogens.
七种人类沉默调节蛋白是一族在全身广泛表达且在进化上保守的依赖烟酰胺腺嘌呤二核苷酸(NAD⁺)的去酰基酶/单磷酸腺苷核糖基转移酶,它们调节众多细胞和机体功能,包括代谢、细胞周期和寿命。在此,我们报告一项发现,即所有七种沉默调节蛋白都具有广泛的抗病毒特性。我们证明,小干扰RNA(siRNA)介导的单个沉默调节蛋白的敲低以及药物介导的沉默调节蛋白酶活性抑制会增加受感染人类细胞中病毒子代的产生。对于DNA病毒和RNA病毒,均观察到了这种对病毒生长的影响。重要的是,沉默调节蛋白激活药物可抑制多种病毒的复制,正如我们在人巨细胞病毒(一种复制缓慢的DNA病毒)和甲型流感(H1N1)病毒(一种快速增殖的RNA病毒)中所证明的那样。此外,沉默调节蛋白的防御功能在进化上是保守的,因为大肠杆菌中的沉默调节蛋白同源物CobB可抵御噬菌体。总之,我们的发现确立了沉默调节蛋白作为免疫防御系统的广谱且在进化上保守的组成部分,为阐明一套新的宿主细胞防御机制以及开发具有抗病毒活性的沉默调节蛋白调节剂提供了框架。
我们生活在病毒的海洋中,其中一些是人类病原体。这些致病病毒表现出众多差异:DNA或RNA基因组、包膜或无包膜病毒粒子、细胞核或细胞质复制、多种疾病症状等。大多数抗病毒药物靶向特定的病毒蛋白。因此它们通常仅对一种病毒有效,并且耐药变体的快速进化可能会损害其疗效。需要鉴定具有广谱抗病毒功能的宿主蛋白,这些蛋白可为限制病毒耐药性进化的治疗提供有效靶点。在此,我们报告沉默调节蛋白为开发广谱抗病毒治疗提供了这样一个机会,因为我们的发现突出了这些酶作为抵御多种病毒病原体的古老防御因子。